Chitosan-Modified PLGA Nanoparticles for Control-Released Drug Delivery

• Main Authors: Boting Lu, Xikun Lv, Yuan Le
• Format: Article
• Language: English
• Published: MDPI AG 2019-02-01
• Series: Polymers
• Subjects: chitosan; PLGA nanoparticles; paclitaxel; drug release
• Online Access: https://www.mdpi.com/2073-4360/11/2/304

Poly (lactic-<i>co</i>-glycolic acid) nanoparticles (PLGA NPs) are well recognized as an ideal drug delivery carrier for their biocompatibility and biodegradability. In order to overcome the disadvantage of drug burst release, chitosan (CS) was used to modify the PLGA nanoparticles. In this work, CS-PLGA nanoparticles with different ratio of CS to PLGA were prepared using high-gravity rotating packed bed (RPB). With the increase of amount of CS, the particle size increased from 132.8 &#177; 1.5 nm to 172.7 &#177; 3.2 nm, zeta potential increased from &#8722;20.8 &#177; 1.1 mV to 25.6 &#177; 0.6 mV, and drug encapsulation efficiency increased from 65.8% to 87.1%. The initial burst release of PLGA NPs reduced after being modified by CS, and the cumulative release was 66.9%, 41.9%, 23.8%, and 14.3%, after 2 h, respectively. The drug release of CS-modified PLGA NPs was faster at pH5.5 than that at pH 7.4. The cellular uptake of CS-modified PLGA NPs increased compared with PLGA NPs, while cell viability was reduced. In conclusion, these results indicated that CS-modified, PTX-loaded PLGA NPs have the advantages of sustained drug release and enhanced drug toxicity, suggesting that CS-modified NPs can be used as carriers of anticancer drugs.